4.5 Article

Progression of Cognitive, Functional, and Neuropsychiatric Symptom Domains in a Population Cohort With Alzheimer Dementia: The Cache County Dementia Progression Study

Journal

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
Volume 19, Issue 6, Pages 532-542

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JGP.0b013e3181faec23

Keywords

Alzheimer disease; Alzheimer dementia; cognition; decline; dementia; neuropsychiatric symptoms; progression

Funding

  1. NIH [R01AG-21136, R01AG11380, R01AG18712, R01HG02213, P30AG028377, K24AG027841, P30AG13846, NIA AG11380, NIA AG028377]
  2. DPS
  3. NIMH
  4. NIA
  5. Associated Jewish Federation of Baltimore
  6. Weinberg Foundation
  7. Forest
  8. Glaxo-Smith-Kline
  9. Eisai
  10. Pfizer
  11. Astra-Zeneca
  12. Lilly
  13. Ortho-McNeil
  14. Bristol-Myers
  15. Novartis

Ask authors/readers for more resources

Objectives: Progression of Alzheimer dementia (AD) is highly variable. Most estimates derive from convenience samples from dementia clinics or research centers where there is substantial potential for survival bias and other distortions. In a population-based sample of incident AD cases, we examined progression of impairment in cognition, function, and neuropsychiatric symptoms, and the influence of selected variables on these domains. Design: Longitudinal, prospective cohort study. Setting: Cache County (Utah). Participants: Three hundred twenty-eight persons with a diagnosis of possible/probable AD. Measurements: Mini-Mental State Exam (MMSE), Clinical Dementia Rating sum-of-boxes (CDR-sb), and Neuropsychiatric Inventory (NPI). Results: Over a mean follow-up of 3.80 (range: 0.07-12.90) years, the mean (SD) annual rates of change were -1.53 (2.69) scale points on the MMSE, 1.44 (1.82) on the CDR-sb, and 2.55 (5.37) on the NPI. Among surviving participants, 30% to 58% progressed less than 1 point per year on these measures, even 5 to 7 years after dementia onset. Rates of change were correlated between MMSE and CDR-sb (r = -0.62, df = 201, p < 0.001) and between the CDR-sb and NPI (r = 0.20, df = 206, p < 0.004). Female subjects (LR chi(2) = 8.7, df = 2, p = 0.013) and those with younger onset (likelihood ratio [LR] chi(2) = 5.7, df = 2, p = 0.058) declined faster on the MMSE. Although one or more apolipoprotein E epsilon 4 alleles and ever use of FDA-approved antidementia medications were associated with initial MMSE scores, neither was related to the rate of progression in any domain. Conclusions: A significant proportion of persons with AD progresses slowly. The results underscore differences between population-based versus clinic-based samples and suggest ongoing need to identify factors that may slow the progression of AD. (Am J Geriatr Psychiatry 2011; 19:532-542)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available